Search Results - "Phelip, J M"

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases by Roblin, Xavier, Rinaudo, M, Del Tedesco, E, Phelip, J M, Genin, C, Peyrin-Biroulet, L, Paul, S

“…Several decision algorithms based on the measurement of infliximab (IFX) trough levels and antibodies to IFX have been proposed. Whether such algorithms can be…”
Get full text

Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference by Launay, M., Guitton, J., Balluet, R., Moreau, A., Phelip, J.-M., Tholance, Y., Gonzalo, P.

Get full text

Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course by Paul, S., Boschetti, G., Rinaudo-Gaujous, M., Moreau, A., Del Tedesco, E., Bonneau, J., Presles, E., Mounsef, F., Clavel, L., Genin, C., Flourié, B., Phelip, J-M., Nancey, S., Roblin, X.

“…Background and Aims: The usefulness of anti-glycan antibodies alone or combined with anti-Saccharomyces cerevisiae [ASCA] or perinuclear antineutrophil…”
Get full text

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer by Mineur, L, François, E, Plassot, C, Phelip, J M, Miglianico, L, Dourthe, L M, Bonichon, N, Moreau, L, Guimbaud, R, Smith, D, Achille, E, Hervé, R, Bons, J M, Remy, S, Faroux, R, Villing, A L, Mahamat, A, Rabbia, I, Soulié, P, Baumgaertner, I, Mathé, N, Vazquez, L, Boustany, R

“…Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data…”
Get full text

Incidence and management of malignant digestive endocrine tumours in a well defined French population by Lepage, C, Bouvier, A M, Phelip, J M, Hatem, C, Vernet, C, Faivre, J

“…Background and aims: Little is known about the epidemiology of malignant digestive endocrine tumours. The aim of this study was to report on their incidence…”
Get full text

Drug interaction between infliximab and azathioprine in patients with Crohn's disease by Roblin, X., Serre‐Debeauvais, F., Phelip, J.‐M., Bessard, G., Bonaz, B.

“…Summary Background : A drug interaction has been observed between infliximab and methotrexate in rheumatoid arthritis. Aim : To look for an interaction between…”
Get full text

Colon cancer in France: evidence for improvement in management and survival by Faivre-Finn, C, Bouvier-Benhamiche, A-M, Phelip, J M, Manfredi, S, Dancourt, V, Faivre, J

“…Background: Cancer registries recording all cases diagnosed in a well defined population represent the only way to assess real changes in the management of…”
Get full text

6‐Tioguanine monitoring in steroid‐dependent patients with inflammatory bowel diseases receiving azathioprine by Roblin, X., Serre‐Debeauvais, F., Phelip, J.‐M., Faucheron, J.‐L., Hardy, G., Chartier, A., Helluwaert, F., Bessard, G., Bonaz, B.

“…Summary Background : 6‐Thioguanine (6‐tioguanine) nucleotides are the active metabolites of azathioprine. Aim : The aim of the study was to evaluate the rate…”
Get full text

Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey by OUSSALAH, A., ROBLIN, X., LAHARIE, D., FILIPPI, J., FLAMANT, M., FAURE, P., PHELIP, J.‐M., BIGARD, M.‐A., PEYRIN‐BIROULET, L.

“…Aliment Pharmacol Ther 30, 854–863 Summary Background  Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several…”
Get full text

Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial by Roblin, X., Boschetti, G., Williet, N., Nancey, S., Marotte, H., Berger, A., Phelip, J. M., Peyrin‐Biroulet, L., Colombel, J. F., Del Tedesco, E., Paul, S., Flourie, B.

“…Summary Background Infliximab (IFX) combined with azathioprine (AZA) is more effective than IFX monotherapy in inflammatory bowel disease (IBD). Aim To…”
Get full text

Surveillance of colorectal cancers following curative-intent surgery: "Whatever the cost?" by Lepage, C., Bouché, O., Phelip, J.M.

Get full text

Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn’s disease by ROBLIN, X., PHELIP, J. M., GENEVOIS, M., DUCROS, V., BONAZ, B.

“…Summary Background A high prevalence of osteoporosis is observed in Crohn’s disease. Recent data have shown that homocysteinaemia is an important risk factor…”
Get full text

Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease by Roblin, X., Marotte, H., Leclerc, M., Del Tedesco, E., Phelip, J.M., Peyrin-Biroulet, L., Paul, S.

“…Background: Antibodies to infliximab [ATI] and trough levels to infliximab [TRI] are associated with loss of response in inflammatory bowel diseases [IBD]. The…”
Get full text

Why do guidelines supersede the conference consensus?: New French recommendations for metastatic colorectal cancer management by Phelip, J.M., Bouche, O., Aparicio, T., Lepage, C.

Get full text

Impact of diabetes mellitus on clinical presentation and prognosis of pancreatic cancer by Dehayem, Y.M, Phelip, J.-M, Kengne, A.-P, Choukem, S.-P, Benhamou, P.-Y, Halimi, S

“…Résumé Introduction Le but de cette étude était de déterminer si l’existence d’un diabète avait une influence sur les manifestations cliniques et le pronostic…”
Get full text

Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer by Taieb, J., Phelip, J.M., Rinaldi, Y., Barbier, E., Bouche, O., Khemissa Akouz, F., Gratet, A., Petorin, C., Miglianico, L., Malka, D., Laharie Mineur, H., Rebischung, C., Lepage, C., Francois, E., Dahan, L.

Get full text

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics by Lepage, C., Phelip, J.-M., Cany, L., Maillard, E., Lievre, A., Chatellier, T., Faroux, R., Duchmann, J.-C., Ben Abdelghani, M., Breysacher, G., Geoffroy, P., Pere-Verge, D., Pelaquier, A., Pillon, D., Ezenfis, J., Rinaldi, Y., Darut-Jouve, A., Duluc, M., Adenis, A., Bouché, O.

Get full text

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial by Touchefeu, Y., Guimbaud, R., Louvet, C., Dahan, L., Samalin, E., Barbier, E., Le Malicot, K., Cohen, R., Gornet, J. M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P. L., Phelip, J. M., Hammel, P., Chapelle, N., Sefrioui, D., Mineur, L., Lepage, C., Bouche, O.

“…Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and…”
Get full text

Appendicectomy as a potential therapy for refractory ulcerative proctitis by Bageacu, S., Coatmeur, O., Lemaitre, J. P., Lointier, P., Del tedesco, E., Phelip, J. M., Roblin, X.

Get full text

Are there regional differences in the management of colon cancer in France? by Phelip, J M, Grosclaude, P, Launoy, G, Colonna, M, Danzon, A, Velten, M, Tretarre, B, Bouvier, A M, Faivre, J

“…The purpose of this study was to assess possible regional disparities in the management of colon cancer in France. In 1995, 1605 patients with a colon cancer…”
Get full text